
In the most recent trading session, Ecopetrol (EC) closed at $14.47, indicating a -1.56% shift from the previous trading day.
Ecopetrol SA is an integrated oil and gas company. The company is headquartered in Bogot, Colombia.
| Revenue (TTM) | $125.67T |
| Gross Profit (TTM) | $41.19T |
| EBITDA | $43.17T |
| Operating Margin | 0.00% |
| Return on Equity | 12.00% |
| Return on Assets | 5.67% |
| Revenue/Share (TTM) | $30563.47 |
| Book Value | $1963.05 |
| Price-to-Book | 1.32 |
| Price-to-Sales (TTM) | 0.92 |
| EV/Revenue | 1.702 |
| EV/EBITDA | 7.10 |
| Quarterly Earnings Growth (YoY) | -7.70% |
| Quarterly Revenue Growth (YoY) | -8.70% |
| Shares Outstanding | $2.06B |
| Float | $473.17M |
| % Insiders | 0.00% |
| % Institutions | 1.32% |
Volatility is currently contracting

In the most recent trading session, Ecopetrol (EC) closed at $14.47, indicating a -1.56% shift from the previous trading day.

BOGOTÁ, Colombia, July 1, 2026 /PRNewswire/ -- Ecopetrol S.A. (BVC: ECOPETROL) (NYSE: EC) (the "Company") hereby announces that the National Government, through Resolution 1492 dated June 30, 2026, issued by the Ministry of Finance and Public Credit ("MHCP"), recognized and ordered payment to the Ecopetrol Group in an aggregate amount of approximately COP 1 trillion, corresponding to the account receivable from the Fuel Price Stabilization Fund ("FEPC") for the second quarter of 2025.

Ecopetrol (EC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

SKYRIZI ® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis 1 Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg 1 Nearly a third of people living with psoriasis develop symptoms before the age of 18, often getting lesions on highly visible areas 2,3 NORTH CHICAGO, Ill., June 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy.

In the most recent trading session, Ecopetrol (EC) closed at $16.25, indicating a -1.99% shift from the previous trading day.

Recently, Zacks.com users have been paying close attention to Ecopetrol (EC). This makes it worthwhile to examine what the stock has in store.

Colombia's state-run oil company Ecopetrol has reached a new collective bargaining agreement with its main workers union (USO), the company said in a statement early on Monday.

BOGOTA D.C., Colombia, June 15, 2026 /PRNewswire/ -- Ecopetrol S.A.

SLB partners with Qualcomm to bring edge AI to energy operations, enabling faster decision-making and greater automation in the field.

WTI near $90 keeps energy in focus: undervalued EC, DINO and NBR trade below sector EV/EBITDA as drilling and margins stay strong.